Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment of Indolent Systemic Mastocytosis With PA101

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02478957
Recruitment Status : Completed
First Posted : June 23, 2015
Last Update Posted : September 29, 2016
Sponsor:
Information provided by (Responsible Party):
Patara Pharma

Brief Summary:

This is a randomized, placebo- and active-controlled, 2-period crossover, 2 cohort study in adult patients with indolent systemic mastocytosis (ISM).

The purpose of the study is to determine the efficacy and safety profile of PA101 delivered via eFlow high efficiency nebulizer in patients with ISM who are symptomatic despite using standard treatments.


Condition or disease Intervention/treatment Phase
Mastocytosis Systemic Mastocytosis Indolent Systemic Mastocytosis Drug: PA101 Drug: Placebo Phase 2

Detailed Description:

The symptom scores for determining eligibility will be established during the 2-week Run-in Period using eDiary and the eligible patients will be randomly allocated in a 2:1 ratio to one of two treatment cohorts at the baseline visit.

In Cohort 1 (n=24), patients will receive inhaled 40 mg PA101 three times daily and inhaled placebo three times daily via eFlow for 6 weeks each in a double-blind, 2-period crossover fashion with a 4-week washout period between the treatment periods.

In Cohort 2 (n=12), patients will receive inhaled 40 mg PA101 three times daily via eFlow and oral cromolyn sodium 200 mg four times daily for 6 weeks each in an open label, 2-period crossover fashion with a 4-week washout period between the treatment periods.

Patients will be allowed to use the same daily doses of pre-randomization H1 and H2 antihistamines as well as the same daily doses of any other allowed medications during each treatment period.

Visits during each treatment period will occur at the baseline Visit, and at the end of Weeks 1, 2, 4, and 6.

Blood and urine samples will be collected to test for various biomarkers. In a subset of patients, additional clinical assessments of the skin will be performed and blood samples will be collected for pharmacokinetic assessments. Clinical safety assessments will be performed in all patients at the start and end of each treatment period.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 41 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Double-blind, Placebo-controlled, Crossover Design, Efficacy and Safety Study With PA101 in Patients With Indolent Systemic Mastocytosis
Study Start Date : June 2015
Actual Primary Completion Date : March 2016
Actual Study Completion Date : June 2016


Arm Intervention/treatment
Experimental: PA101
PA101, 40 mg administered via inhalation three times daily for 6 weeks
Drug: PA101
40 mg PA101 administered via inhalation three times daily for 6 weeks

Placebo Comparator: Placebo
Placebo, administered via inhalation three times daily for 6 weeks
Drug: Placebo
matching placebo administered via inhalation three times daily for 6 weeks




Primary Outcome Measures :
  1. Overall symptom score [ Time Frame: 6 weeks ]
    Mastocytosis Activity of Symptoms (MAS Plus) questionnaire for daily symptom score using eDiary


Secondary Outcome Measures :
  1. Disease specific quality of life (QoL) [ Time Frame: 6 weeks ]
    Mastocytosis Impact Questionnaire (MIQ) for quality of life

  2. Patient Global Impression of Change (PGIC) scale [ Time Frame: 6 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of indolent systemic mastocytosis (ISM) according to the WHO criteria and the consensus proposal (2001)
  • Experiencing at least one predefined qualifying symptom in at least two organ systems within 3 months of Screening despite the use of H1 and/or H2 antihistamines and other anti-mediator therapy
  • Experiencing symptoms with a severity score of at least 4 for at least 7 out of 14 days during the Run-in period with at least one predefined qualifying symptom each from at least two organ systems, despite the use of H1 and/or H2 antihistamines and/or other anti-mediator therapy
  • Willing and able to use an eDiary device daily for the duration of the study
  • Completed at least 5 eDiary reports during each of two consecutive weeks of the Run-in period
  • Willing and able to provide written informed consent prior to any study procedures

Exclusion Criteria:

  • Advanced systemic mastocytosis (i.e., aggressive systemic mastocytosis [ASM], mast cell leukemia [MCL], or systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease [SM-AHNMD] )
  • Current or recent history of clinically significant cardiovascular, hematological, renal, neurologic, hepatic, endocrine, psychiatric, malignant, or other illnesses that could put the patient at risk or compromise the quality of the study data as determined by the Investigator
  • Use of oral cromolyn sodium within 6 weeks of Screening
  • History of systemic corticosteroid, immunosuppressive, or anti-IgE monoclonal antibody therapy (e.g., omalizumab) within 6 months of Screening
  • History of anaphylaxis requiring systemic treatment (i.e., corticosteroid or epinephrine) within 12 months of Screening
  • Upper or lower respiratory tract infection within 4 weeks of Screening
  • History of malignancy within the last 5 years, except basal cell carcinoma or cervix carcinoma in situ
  • Major surgery within 6 months of Screening
  • Current or recent history (within 12 months) of excessive use or abuse of alcohol
  • Current or recent history (within 12 months) of abusing legal drugs or use of illegal drugs or substances
  • Pregnant or breastfeeding females, or if of child-bearing potential unwilling to practice acceptable means of birth control or abstinence during the study
  • Participation in any other investigational drug study within 4 weeks of Screening
  • History of hypersensitivity or intolerance to aerosol medications or cromolyn sodium

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02478957


Locations
Layout table for location information
France
Hopital Necker - Enfants Malades
Paris, France
Germany
Charité - Universitätsmedizin Berlin
Berlin, Germany
Klinikum Darmstadt
Darmstadt, Germany
University Medical Center Mainz
Mainz, Germany
Technical University München
Munich, Germany
Italy
University of Salerno
Salerno, Italy
Netherlands
University Medical Center of Groningen
Groningen, Netherlands
Spain
Hospital Universitario de Fuenlabrada
Madrid, Spain
Sponsors and Collaborators
Patara Pharma
Investigators
Layout table for investigator information
Principal Investigator: Frank Siebenhaar, MD Charite University, Berlin, Germany

Layout table for additonal information
Responsible Party: Patara Pharma
ClinicalTrials.gov Identifier: NCT02478957     History of Changes
Other Study ID Numbers: PA101-SM-02
First Posted: June 23, 2015    Key Record Dates
Last Update Posted: September 29, 2016
Last Verified: September 2016
Keywords provided by Patara Pharma:
mastocytosis
cromolyn sodium
Additional relevant MeSH terms:
Layout table for MeSH terms
Mastocytosis
Mastocytosis, Systemic
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Skin Diseases
Immune Complex Diseases
Hypersensitivity
Immune System Diseases